SCHEMBL27224726

SCHEMBL27224726

COc1ccc(CNc2nccc(Cc3ncc(Nc4ccc([Si](C)(C)C)cc4F)c(C(=O)O)c3C)c2F)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 1/20 0.41
▸ MAPT P10636 2/20 0.39
▸ CYP1A2 P05177 12/20 0.36
▸ CYP3A4 P08684 12/20 0.36
▸ CYP2C19 P33261 12/20 0.36
▸ CYP2D6 P10635 10/20 0.36
▸ CLK4 Q9HAZ1 5/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ KDR P35968 1/20 0.36
▸ TSHR P16473 8/20 0.35
▸ USP2 O75604 7/20 0.35
▸ ALDH1A1 P00352 6/20 0.35
▸ HSD17B10 Q99714 5/20 0.35
▸ MAPK1 P28482 5/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ KMT2A Q03164 4/20 0.34
▸ MEN1 O00255 3/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ LMNA P02545 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27224637 0.86 KDM4C (0.46) KDM4CMAPTCYP1A2CYP3A4CYP2C19
SCHEMBL30135702 0.85 CYP1A2 (0.39) MAPTCYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL24849056 0.83 MAPT (0.42) KDM4CMAPTCYP1A2CYP3A4CYP2C19
SCHEMBL31236928 0.83 MAPT (0.42) KDM4CMAPTCYP1A2CYP3A4CYP2C19
SCHEMBL31401688 0.76 CYP1A2 (0.44) KDM4CMAPTCYP1A2CYP3A4CYP2C19
SCHEMBL30746514 0.75 CYP1A2 (0.40) KDM4CMAPTCYP1A2CYP3A4CYP2C19
SCHEMBL26984959 0.75 CYP1A2 (0.40) KDM4CMAPTCYP1A2CYP3A4CYP2C19
SCHEMBL29425460 0.72 AURKA (0.46) KDM4CMAPTKDR
SCHEMBL27224639 0.72 AURKA (0.46) KDM4CMAPTKDR
SCHEMBL38651248 0.72 MAPT (0.44) KDM4CMAPTCYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327355-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-10-03 — — US disclosed
EP-4375273-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327355-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE BRAF, RAF1, NRAS KDM4C 273/4885MAPT 3820/4885CYP1A2 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback